Therapeutic Action
Hormonal contraceptive, progestogen
PDF page 400
Loading InternPractice…
Drug reference
Hormonal contraceptive, progestogen
PDF page 400
Long-acting contraception
PDF page 400
Do not administer to patients with breast cancer, severe or recent liver disease, unexplained vaginal bleeding, active thromboembolic disorders. May cause: menstrual irregularities, amenorrhoea, menometrorrhagia, breast tenderness, headache, weight gain, itching, acne, mood changes, abdominal pain, gastrointestinal disturbances, allergic reactions. Enzyme-inducing drugs (rifampicin, rifabutin, efavirenz, nevirapine, lopinavir, ritonavir, phenobarbital, phenytoin, carbamazepine, griseofulvin, etc.) reduce the effectiveness of the contraceptive. Pregnancy: CONTRA-INDICATED Breast-feeding: no contra-indication
PDF pages 400, 401
Flexible rod containing 68 mg of etonogestrel, in a sterile disposable applicator, to be inserted subdermally into the inner side of the non-dominant arm, 6 to 8 cm above the elbow crease, under local anaesthesia and aseptic conditions
PDF page 400
The implant may be inserted at any moment of the cycle if it is reasonably certain the woman is not pregnant, including when switching from another form of contraception. Use condoms for 7 days after insertion of the implant if it is inserted: more than 7 days after the start of menstruation; more than 28 days postpartum if not breastfeeding; more than 7 days after an abortion.
PDF page 400
As long as this method of contraception is desired and it is well tolerated, for max. 3 years after which it no longer provides contraception and must be changed.
PDF page 400
Fertility returns rapidly after removal of the implant. For the conditions for insertion or removal the implant, follow manufacturer’s instructions.
PDF page 401
– Below 25 °C
PDF page 401